Actively Recruiting
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Led by Sichuan University · Updated on 2026-05-08
40
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations who have progressed following standard TKI therapy.
CONDITIONS
Official Title
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent provided
- Age between 18 and 80 years old
- Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations
- EGFR-sensitive mutations including exon 19 deletion, exon 21 L858R, or exon 20 T790M mutated
- Predicted life expectancy of at least 12 weeks
- Resistance or intolerance to standard EGFR TKI therapy
- No previous systemic chemotherapy for advanced or metastatic disease
- Adequate organ function
- Measurable disease according to RECIST 1.1
- Patients with stable or pre-treated brain metastasis can participate
You will not qualify if you...
- Spinal cord compression or meningeal metastasis
- History of malignant tumors within the past 2 years
- Known resistant mutations with approved targeted therapy
- Not recovered from adverse events caused by previous treatment
- History of stroke or intracranial hemorrhage within 6 months before initial dosing
- Any severe or poorly controlled systemic disease including active infections such as hepatitis B, hepatitis C, or HIV
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610044
Actively Recruiting
Research Team
L
Li Li, BA
CONTACT
F
Feifei Na, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here